The Group acquires 51% of kidney dialysis operator to offer holistic management of kidney health for dialysis patients

PETALING JAYA, Malaysia - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is acquiring a 51% stake in Aquahealth Sdn Bhd, a kidney dialysis operator, from Rinani Renal Berhad.

Aquahealth is establishing a kidney dialysis centre in Gombak, Selangor, with the license to operate the centre owned by the Malaysia International Islamic Chamber of Commerce. With the acquisition of the stake, Malaysian Genomics, through its wholly-owned subsidiary, MGRC Healthcare Sdn Bhd, will now become the operator of the dialysis centre.

En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "This will be the first of many centres across the country that will be driven by a personalised kidney care model integrating dialysis with nutrition management, lifestyle changes, and even genetic testing of patients and their immediate family members. This pioneering approach will focus on bringing innovations in service delivery to improve the lives of patients with chronic kidney years."

According to the Ministry of Health's Management of Chronic Kidney Disease report, the number of Malaysians with kidney disease is projected to increase significantly in the future mainly due to the prevalence of diabetes, hypertension and an aging population[1]. At 13.2% per year, Malaysia has the second highest annual growth rate of chronic kidney disease in the world[2].

Dato' Dr. Suhaini Kadiman, Chairman of Malaysia International Islamic Chamber of Commerce and Director of Clinical Research at Institute Jantung Negara added, "Thousands of kidney patients are on waiting lists for dialysis treatment and new centres are urgently needed. We welcome MGRC Healthcare's interest to collaborate with us to operate the centre in Gombak, and we look forward to the innovations they will contribute to improve the lives of kidney dialysis

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE